Quagen Company Profile
✉ Email this page to a colleague
What is the competitive landscape for QUAGEN, and what generic and branded alternatives to QUAGEN drugs are available?
QUAGEN has twenty-five approved drugs.
Drugs and US Patents for Quagen
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Quagen | BUTALBITAL, ACETAMINOPHEN AND CAFFEINE | acetaminophen; butalbital; caffeine | CAPSULE;ORAL | 216376-001 | Mar 12, 2024 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Quagen | CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY | cetirizine hydrochloride | SOLUTION;ORAL | 212266-001 | May 16, 2019 | OTC | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Quagen | ALBUTEROL SULFATE | albuterol sulfate | SYRUP;ORAL | 212197-001 | Sep 6, 2019 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Quagen | FLUOCINOLONE ACETONIDE | fluocinolone acetonide | OIL;TOPICAL | 212761-001 | Apr 2, 2021 | AT | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Quagen | FLUOCINOLONE ACETONIDE | fluocinolone acetonide | OIL/DROPS;OTIC | 212762-001 | Apr 2, 2021 | AT | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Quagen | CYPROHEPTADINE HYDROCHLORIDE | cyproheptadine hydrochloride | SYRUP;ORAL | 212423-001 | May 22, 2019 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.